ClinicalTrials.gg
Not yet recruitingNCT07502963PREDUUpdated Mar 31, 2026

Effectiveness of a Multimodal Outpatient Supervised Physical Activity Program to Improve Tolerance and Efficacy of Chemotherapy in Adults With Breast, Lung and Colon Cancer

An interventional study of PREDU Exercise Program and Recommendation Exercise Program in Breast Cancer, Lung Cancer (Non-Small Cell) and Colorectal Cancer, sponsored by University of Vic - Central University of Catalonia. Not yet recruiting at 3 sites in Spain. Open to participants aged 35 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-31.

Sponsored by University of Vic - Central University of Catalonia · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
35 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 905 studies in Breast Neoplasms with a site in Spain — 164 open to participants now, 285 under way, 84 of them phase 3. Breast Neoplasms · Spain.

Planned enrollment
585th of 805
70 · median 151
Started
2026
with 26 others
No phase
146 of 905
51 open now
Primary completion
2027-04
later than 145 of 284 live
Registered
886th of 905
by date

Among the 905 studies in Breast Neoplasms with a site in Spain, this one is the 585th largest by planned enrollment of the 805 interventional ones that give a count, is one of 27 that started in 2026, is one of 146 with no phase, reaches primary completion later than 145 of the 284 other live ones, and was the 886th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

164 of the 905 studies in Breast Neoplasms with a site in Spain are open now. Recruiting first, the newest first:

159 more — sign in →

All 164 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 35 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 905 studies in Breast Neoplasms with a site in Spain, or all of them as a file.
02

Study summary

This clinical study evaluates whether a supervised, multimodal therapeutic exercise program started before chemotherapy and continued during treatment can improve treatment outcomes in patients aged 35 to 65 years with breast, lung, or colon cancer.

The study hypothesis is that participation in this exercise program improves tolerance to chemotherapy, allowing patients to receive more than 85% of the planned relative dose intensity. In addition, the program is expected to enhance treatment effectiveness by increasing the rate of complete radiological response.

The main objective of the study is to assess the effectiveness of a supervised, multimodal therapeutic exercise program performed before and during chemotherapy in improving both treatment tolerance and treatment efficacy in patients with breast, lung, and colon cancer.

Read the detailed description

This study proposes a randomized, stratified, assessor-blinded, longitudinal, prospective clinical trial designed in accordance with the CONSORT guidelines.

This study is justified by the need to identify effective strategies to improve chemotherapy tolerance and efficacy, as well as to reduce adverse effects and preserve patients' quality of life. The available scientific evidence suggests that multimodal physical activity programs combining cardiovascular and strength training, particularly when supervised, individualized, initiated before treatment, and maintained throughout chemotherapy, may exert a positive impact on chemotherapy tolerance and efficacy. These variables are key determinants in achieving favorable indicators and in improving the side effects caused by chemotherapy.

OBJECTIVES AND HYPOTHESIS The primary objective is to evaluate the effectiveness of a supervised multimodal therapeutic exercise program, initiated before and maintained during chemotherapy, on treatment tolerance and efficacy in patients aged 35 to 65 years diagnosed with breast, lung, or colorectal cancer.

The following outcomes will be compared between the experimental and control groups:

  • Relative Dose Intensity (RDI)
  • Treatment completion rate
  • Radiological or pathological complete response

Secondary objectives include comparing the evolution of cancer-related fatigue, quality of life, muscular strength, cardiorespiratory capacity, and adherence to physical activity between both groups. Additionally, the study will explore whether tumor location, cancer stage, and age moderate the effect of the intervention on treatment tolerance and efficacy, as well as on secondary outcomes.

The main hypothesis is that participants performing supervised therapeutic exercise will more frequently achieve an RDI ≥85% compared to the control group and will demonstrate improved therapeutic efficacy outcomes.

STUDY DESIGN

Two parallel groups will be included:

Experimental Group (EG): supervised therapeutic exercise program Control Group (CG): unsupervised home-based physical activity with general recommendations

Randomization will be stratified according to cancer location (breast, lung, or colorectal) to ensure balance between groups. Allocation will be generated using computer software. Outcome assessors will be blinded to group assignment.

INTERVENTION

The total duration of the program will be 48 weeks, including 18 weeks of active intervention during chemotherapy and 24 weeks of follow-up after treatment completion.

CONTROL GROUP

Participants in the control group will receive standardized verbal and written recommendations to perform therapeutic physical activity at home in accordance with World Health Organization guidelines.

Recommendations will include:

3-4 weekly sessions of aerobic exercise (30-45 minutes at approximately 70% of maximum heart rate), such as walking, brisk walking, cycling, swimming, or rowing.

2 weekly strength-training sessions (approximately 30 minutes), including upper limb, trunk, and lower limb exercises at intensities between 50-80% of one-repetition maximum (1RM), consisting of 2 sets of 8-12 repetitions, using body weight and elastic resistance bands.

Low-intensity joint mobility exercises. These activities will not be supervised or individualized by the research team.

EXPERIMENTAL GROUP

Participants in the experimental group will perform supervised and individualized therapeutic exercise sessions in specialized centers. The program will be adapted according to fatigue levels and the phase of the chemotherapy cycle.

Three supervised sessions per week will be conducted:

One session focused on aerobic exercise (45 minutes), combining moderate continuous training (approximately 70% of maximum heart rate) with moderate interval training (>85% of maximum heart rate alternating with 50% of maximum heart rate), including Low-Intensity High-Intensity Interval Training (Low HIIT).

Two combined sessions (50 minutes each), including:

30 minutes of aerobic exercise 20 minutes of strength training at intensities between 50-80% of 1RM, 2 sets of 8-12 repetitions, using guided machines, elastic resistance bands, and free weights.

Exercises will target the main muscle groups (quadriceps, hamstrings, gluteal muscles, pectoralis major, latissimus dorsi, biceps, triceps, and lumbar musculature). All sessions will include low-intensity joint mobility exercises.

PROCEDURE AND ASSESSMENTS

Four assessment time points will be conducted:

Baseline (at diagnosis) At the start of chemotherapy At completion of chemotherapy At 24 weeks after completion of the intervention

The general areas assessed will include:

Relative Dose Intensity (RDI) Radiological complete response (RRC) Dynamic and static muscular strength Cardiorespiratory capacity Cancer-related fatigue Quality of life Adherence to physical activity

03

Conditions studied

  • Breast Cancer
  • Lung Cancer (Non-Small Cell)
  • Colorectal Cancer
  • Physical Activity
  • Neoadjuvant Chemotherapy Tolerance
  • Strength and Endurance

Keywords

  • Breast Cancer
  • Lung Cancer (Non-Small Cell)
  • Colorectal cancer
  • Physical Activity
  • Strength and endurance
  • Neoadjuvant Chemotherapy Tolerance
04

Who can participate

Ages eligible
35 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women and men aged 35 to 65 years
  • Diagnosed with stage II, III, or IV breast, lung, or colon cancer
  • Scheduled to start chemotherapy
  • Able and willing to provide written

Exclusion criteria

Exclusion Criteria:

  • Musculoskeletal or neurological disorders that prevent proper execution of the exercises
  • Uncontrolled infections or symptoms
  • Comorbidities such as (COPD), respiratory failure, or recent cardiovascular events within the past 6 months
  • (BMI) over 35
  • Pregnant women
  • Difficulty understanding the purpose and procedures of the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Active comparator
    Control group

    An exercise program based on guidance provided during the informational session and the provided brochure is followed, without planning, adaptation, or supervision. Recommendations include aerobic and strength training exercises.

    Other: Recommendation Exercise Program

  • Experimental
    Experimental group

    A supervised, planned, and adapted therapeutic physical exercise program is implemented according to fatigue levels and the phase of the neoadjuvant chemotherapy cycle. The program includes three supervised sessions per week combining aerobic and strength training exercises.

    Other: PREDU Exercise Program

Interventions

  • OtherPREDU Exercise Program

    The intervention includes a supervised, multimodal therapeutic exercise program in two phases: 2 weeks before chemotherapy and 16 weeks during chemotherapy. Pre-chemotherapy (2 weeks): 3 weekly home-based aerobic sessions and 2 supervised strength sessions (30 min each) using free weights or guided equipment. During chemotherapy (16 weeks): 3 supervised sessions per week combining aerobic and strength training (20-50 min each). Aerobic exercises use stationary cycling or treadmill moderate continuous (70% HRmax) and interval training (Low HIIT 85%HRmax). Strength exercises are 2 sets of 8-12 reps at 50-80% of 1RM, using guided weights and elastic bands. The program is adapted and planned according to participants' fatigue and chemotherapy cycle.

  • OtherRecommendation Exercise Program

    Participants follow unsupervised exercise recommendations during the 2 weeks before and the 16 weeks of chemotherapy. Aerobic exercises are 30-45 minutes, 3-4 times per week (walking, swimming, cycling), and strength exercises are 2 sessions per week, 30 minutes each, targeting upper limbs, trunk, and lower limbs. Participants are responsible for following these recommendations on their own, without individualized adaptation or supervision, aiming to meet WHO exercise guidelines for oncology populations.

06

What researchers measure

Primary outcomes

  1. Chemotherapy Treatment Tolerance assessed by Relative Dose Intensity (RDI)

    Percentage of relative dose intensity (RDI), calculated as the ratio between planned chemotherapy dose and administered dose, expressed as a percentage. Data are obtained from medical clinical records. Compare the results between the groups.

    Time frame: Evaluation at the start of chemotherapy (2 weeks after the beginning of the PREDU intervention) and at the end of chemotherapy (18 weeks after the PREDU intervention).

  2. Complete Response (CR) Rate according to RECIST 1.1 Criteria

    Percentage of participants achieving complete response (CR), defined as the disappearance of all target lesions and reduction of pathological lymph nodes to \<10 mm, assessed using the RECIST 1.1 criteria scale. Data are obtained from medical clinical records. Compare the results between the groups.

    Time frame: CR is evaluated at baseline (diagnosis) and at the end of chemotherapy (18 weeks after the PREDU intervention).

Secondary outcomes

  1. Cancer-Related Fatigue Score assessed by Piper Fatigue Scale

    Fatigue is measured using the Piper Fatigue Scale, a self-reported instrument with 22 items scored from 0 to 10, where higher scores indicate greater fatigue. The scale evaluates four dimensions of subjective fatigue: severity, sensory impact, cognitive impact, and mood. The total fatigue score is calculated by summing the scores of the four dimensions and dividing by four. Measured on a numerical scale from 0 to 10. Compare the results of the four assessments and between the groups.

    Time frame: Measurements are performed at baseline, at 2 weeks, at 18 weeks, and at 24 weeks after completion of the intervention.

  2. Static muscle strenght (kg) assessed by Handheld Dynamometer

    Peak muscle strength, expressed in kilograms (kg), assessed using a handheld dynamometer. Comparisons are made across all four assessments and between the groups.

    Time frame: Measurements are performed at baseline, at 2 weeks, at 18 weeks, and at 24 weeks after completion of the intervention.

  3. Dynamic Muscle Strength (kg) using Brzycki Equation

    Estimated dynamic muscle strength, expressed in kilograms (kg), calculated from n-repetition maximum (n-RM) using the Brzycki equation.

    Time frame: Measurements are performed at baseline, at 2 weeks, at 18 weeks, and at 24 weeks after completion of the intervention.

  4. Change in Quality of Life Score

    Quality of life is assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). Scores are on a 0-100 scale, with higher scores indicating better functioning or quality of life, whereas for symptom scales, higher scores indicate greater symptom burden. Compare the results of the four assessments and between the groups.

    Time frame: Measurements are performed at baseline, at 2 weeks, at 18 weeks, and at 24 weeks after completion of the intervention.

  5. Change in Cardiorespiratory Capacity

    Cardiorespiratory capacity is assessed using the 6-Minute Walk Test (6MWT), a submaximal field test in which participants walk the greatest distance possible in 6 minutes along a 30-meter flat course. Exercise tolerance is evaluated through the distance walked (meters) and estimated VO₂max. Higher values indicate better cardiorespiratory fitness. Assessments are conducted at all four time points, and results are compared between the groups.

    Time frame: Measurements are performed at baseline, at 2 weeks, at 18 weeks, and at 24 weeks after completion of the intervention.

  6. Percentage of Participants in Each Stage of Change Physical Activity Adherence

    Percentage of participants in each stage of change for physical activity, assessed using the Transtheoretical Model. Data are collected at each assessment point and compared between the control and experimental groups.

    Time frame: Measurements are performed at baseline, at 2 weeks, at 18 weeks, and at 24 weeks after completion of the intervention.

  7. Percentage of Participants by Physical Activity Adherence Level

    Percentage of participants achieving each level of moderate and vigorous physical activity (minutes per week), assessed and compared between the control and experimental groups to evaluate changes in adherence to physical activity.

    Time frame: Assessed at baseline and at 24 weeks after completion of the intervention.

  8. To explore whether tumor location, stage, and age moderate the effect of the intervention on treatment tolerance and efficacy

    Compare the primary and secondary outcome results by tumor location, stage, and age to explore whether outcomes differ between these subgroups.

    Time frame: Assessments are conducted from the first evaluation up to the third evaluation at 18 weeks.

07

Study locations

3 sites
  • Consorci Hospitalari de Vic
    Vic, Barcelona 08500, Spain
    • · Contact(+34) 93 889 11 11
  • Facultat de Ciències de la Salut i del Benestar de la Universitat de Vic (UVIC-UCC) Universitat de Vic- Universitat Central de Catalunya
    Vic, Barcelona 08500, Spain
  • Hospital Universitari de la Santa Creu
    Vic, Barcelona 08500, Spain
08

References and documents

Publications

  • Kjeldsted E, Ammitzboll G, Laenkholm AV, Rasic D, Ceballos SG, Jorgensen LB, Skou ST, Bojesen RD, Lodin A, Tolver A, Rosthoj S, Jack S, Gehl J, Dalton SO. Effects of Supervised Exercise during Neoadjuvant Chemotherapy on Tumor Response in Patients with Breast Cancer (Neo-train): A Randomized Controlled Trial. Clin Cancer Res. 2025 Oct 15;31(20):4265-4277. doi: 10.1158/1078-0432.CCR-25-0416. PubMed 40788186 ↗
  • Schmidt ME, Goldschmidt S, Kreutz C, Muller J, Schneeweiss A, May AM, Rosenberger F, Wiskemann J, Steindorf K. Effects of aerobic or resistance exercise during neoadjuvant chemotherapy on tumor response and therapy completion in women with breast cancer: The randomized controlled BENEFIT trial. J Sport Health Sci. 2025 Dec;14:101064. doi: 10.1016/j.jshs.2025.101064. Epub 2025 May 28. PubMed 40447136 ↗
  • Ormel HL, van der Schoot GGF, Sluiter WJ, Jalving M, Gietema JA, Walenkamp AME. Predictors of adherence to exercise interventions during and after cancer treatment: A systematic review. Psychooncology. 2018 Mar;27(3):713-724. doi: 10.1002/pon.4612. Epub 2018 Jan 26. PubMed 29247584 ↗
  • But-Hadzic J, Dervisevic M, Karpljuk D, Videmsek M, Dervisevic E, Paravlic A, Hadzic V, Tomazin K. Six-Minute Walk Distance in Breast Cancer Survivors-A Systematic Review with Meta-Analysis. Int J Environ Res Public Health. 2021 Mar 5;18(5):2591. doi: 10.3390/ijerph18052591. PubMed 33807611 ↗
  • van der Schoot GGF, Ormel HL, Westerink NL, May AM, Elias SG, Hummel YM, Lefrandt JD, van der Meer P, van Melle JP, Poppema BJ, Stel JMA, van der Velden AWG, Vrieling AH, Wempe JB, Ten Wolde MG, Nijland M, de Vries EGE, Gietema JA, Walenkamp AME. Optimal Timing of a Physical Exercise Intervention to Improve Cardiorespiratory Fitness: During or After Chemotherapy. JACC CardioOncol. 2022 Oct 18;4(4):491-503. doi: 10.1016/j.jaccao.2022.07.006. eCollection 2022 Nov. PubMed 36444224 ↗
  • Groen WG, Naaktgeboren WR, van Harten WH, van Vulpen JK, Kool N, Sonke GS, van der Wall E, Velthuis MJ, Aaronson NK, May AM, Stuiver MM. Physical Fitness and Chemotherapy Tolerance in Patients with Early-Stage Breast Cancer. Med Sci Sports Exerc. 2022 Apr 1;54(4):537-542. doi: 10.1249/MSS.0000000000002828. PubMed 34961754 ↗
  • Campbell KL, Winters-Stone KM, Wiskemann J, May AM, Schwartz AL, Courneya KS, Zucker DS, Matthews CE, Ligibel JA, Gerber LH, Morris GS, Patel AV, Hue TF, Perna FM, Schmitz KH. Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable. Med Sci Sports Exerc. 2019 Nov;51(11):2375-2390. doi: 10.1249/MSS.0000000000002116. PubMed 31626055 ↗
  • Ficarra S, Thomas E, Bianco A, Gentile A, Thaller P, Grassadonio F, Papakonstantinou S, Schulz T, Olson N, Martin A, Wagner C, Nordstrom A, Hofmann H. Impact of exercise interventions on physical fitness in breast cancer patients and survivors: a systematic review. Breast Cancer. 2022 May;29(3):402-418. doi: 10.1007/s12282-022-01347-z. Epub 2022 Mar 12. PubMed 35278203 ↗
  • Baker JL, Di Meglio A, Gbenou AS, El Mouhebb M, Iyengar NM, Michiels S, Cottu P, Lerebours F, Coutant C, Lesur A, Tredan O, Vanlemmens L, Jouannaud C, Hrab I, Everhard S, Martin AL, Arveux P, Fabrice A, Vaz-Luis I, Jones LW. Association between physical activity and neoadjuvant chemotherapy completion and pathologic complete response in primary breast cancer: the CANTO study. Br J Cancer. 2022 Sep;127(5):886-891. doi: 10.1038/s41416-022-01870-y. Epub 2022 Jun 17. PubMed 35715631 ↗
  • Lin D, Sturgeon KM, Muscat JE, Zhou S, Hobkirk AL, O'Brien KM, Sandler DP, Thompson CL. Associations of pre-diagnosis physical activity with treatment tolerance and treatment efficacy in breast cancer patients with neoadjuvant chemotherapy. Breast Cancer. 2024 May;31(3):519-528. doi: 10.1007/s12282-024-01569-3. Epub 2024 Apr 2. PubMed 38564089 ↗
  • Matthews CE, Moore SC, Arem H, Cook MB, Trabert B, Hakansson N, Larsson SC, Wolk A, Gapstur SM, Lynch BM, Milne RL, Freedman ND, Huang WY, Berrington de Gonzalez A, Kitahara CM, Linet MS, Shiroma EJ, Sandin S, Patel AV, Lee IM. Amount and Intensity of Leisure-Time Physical Activity and Lower Cancer Risk. J Clin Oncol. 2020 Mar 1;38(7):686-697. doi: 10.1200/JCO.19.02407. Epub 2019 Dec 26. PubMed 31877085 ↗
  • Koelwyn GJ, Quail DF, Zhang X, White RM, Jones LW. Exercise-dependent regulation of the tumour microenvironment. Nat Rev Cancer. 2017 Sep 25;17(10):620-632. doi: 10.1038/nrc.2017.78. PubMed 28943640 ↗
  • Christianson JB, Wholey DR, Sanchez SM. State responses to HMO failures. Health Aff (Millwood). 1991 Winter;10(4):78-92. doi: 10.1377/hlthaff.10.4.78. No abstract available. PubMed 1778570 ↗
  • Montano-Rojas LS, Romero-Perez EM, Medina-Perez C, Reguera-Garcia MM, de Paz JA. Resistance Training in Breast Cancer Survivors: A Systematic Review of Exercise Programs. Int J Environ Res Public Health. 2020 Sep 7;17(18):6511. doi: 10.3390/ijerph17186511. PubMed 32906761 ↗
  • Juvet LK, Thune I, Elvsaas IKO, Fors EA, Lundgren S, Bertheussen G, Leivseth G, Oldervoll LM. The effect of exercise on fatigue and physical functioning in breast cancer patients during and after treatment and at 6 months follow-up: A meta-analysis. Breast. 2017 Jun;33:166-177. doi: 10.1016/j.breast.2017.04.003. Epub 2017 Apr 14. PubMed 28415013 ↗
  • Usiskin I, Li F, Irwin ML, Cartmel B, Sanft T. Association between pre-diagnosis BMI, physical activity, pathologic complete response, and chemotherapy completion in women treated with neoadjuvant chemotherapy for breast cancer. Breast Cancer. 2019 Nov;26(6):719-728. doi: 10.1007/s12282-019-00974-3. Epub 2019 May 22. PubMed 31119682 ↗
  • Sanft T, Harrigan M, McGowan C, Cartmel B, Zupa M, Li FY, Ferrucci LM, Puklin L, Cao A, Nguyen TH, Neuhouser ML, Hershman DL, Basen-Engquist K, Jones BA, Knobf T, Chagpar AB, Silber A, Tanasijevic A, Ligibel JA, Irwin ML. Randomized Trial of Exercise and Nutrition on Chemotherapy Completion and Pathologic Complete Response in Women With Breast Cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis Study. J Clin Oncol. 2023 Dec 1;41(34):5285-5295. doi: 10.1200/JCO.23.00871. Epub 2023 Sep 1. PubMed 37656930 ↗
  • Denduluri N, Lyman GH, Wang Y, Morrow PK, Barron R, Patt D, Bhowmik D, Li X, Bhor M, Fox P, Dhanda R, Saravanan S, Jiao X, Garcia J, Crawford J. Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian Cancer. Clin Breast Cancer. 2018 Oct;18(5):380-386. doi: 10.1016/j.clbc.2018.02.003. Epub 2018 Feb 16. PubMed 29622384 ↗
  • Bland KA, Zadravec K, Landry T, Weller S, Meyers L, Campbell KL. Impact of exercise on chemotherapy completion rate: A systematic review of the evidence and recommendations for future exercise oncology research. Crit Rev Oncol Hematol. 2019 Apr;136:79-85. doi: 10.1016/j.critrevonc.2019.02.005. Epub 2019 Feb 16. PubMed 30878132 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Apr 2027, 12 months later.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 12 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2026
First posted
Mar 31, 2026
StartEst.
Apr 2026
Primary completionEst.
Apr 2027
CompletionEst.
Oct 2027
Last update
Mar 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07502963
Lead sponsor
University of Vic - Central University of Catalonia
Collaborators
Col·legi Fisioterapeutes de Catalunya
Responsible party
Meritxell Parareda (Principal Investigator Professor Meritxell Parareda Ventura, University of Vic - Central University of Catalonia) — Principal investigator
First posted
Mar 31, 2026
Start date
Apr 2026 (estimated)
Primary completion
Apr 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Mar 31, 2026

Study contacts

Meritxell Parareda Ventura, Physiotherapist
Contact
meritxell.parareda@uvic.cat
(+34) 93 881 60 25

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion